HTA submissions

Health technology assessment (HTA) is a multidisciplinary field that studies the medical, social, ethical and economic considerations of a health technology – usually a drug, medical device, diagnostic or clinical/surgical procedure. HTA seeks to provide health policy-makers with accessible, usable and evidence-based information to guide decisions on the appropriate use of health technologies, and the efficient allocation of resources.

A positive HTA is often crucial to the success of any new product, opening the door to widespread prescribing. But preparing an HTA submission can seem like a daunting task.

Hayward has been compiling submissions to the UK’s major HTA bodies – the National Institute for Health and Care Excellence (NICE), Scottish Medicines Consortium (SMC) and All Wales Medicines Strategy Group (AWMSG) – since their inception, with a high overall success rate.

Our know-how, attention to detail and access to key opinion leaders and top health economists all combine to provide you with the best possible submission.

In the last five years alone, Hayward has been involved in 40 submissions to HTA bodies in the UK and Republic of Ireland, and has several submissions currently in progress. Hayward’s successful approach, developed over numerous submissions, has also benefited from close relationships with key members, both past and present, of the HTA bodies.

We can also help you turn a negative HTA decision into a positive one; our success rates with first and second re-submission are over 70%, regardless of our involvement in the previous submissions.

We have supported clients working with a range of European HTA bodies – France’s High Authority for Health (HAS), the German Institute for Quality and Efficiency in Health Care (IQWiG), Ireland’s National Centre for Pharmacoeconomics

Committee (CPR), Spain’s Institute of Health Carlos III (ISCIII), the Dental and Pharmaceutical Benefits Agency (TLV) in Sweden – and even product classification applications to the World Health Organization (WHO).

Achieving a positive HTA outcome is only half the story; clinicians, pharmacists and budget holders also need to be told about it. We can identify the right communication channel and deliver your message to those who need to know.

To find out more about how we can help you, call +44(0)1638 723560 or email Paul Thomas